Overall, data obtained highlight the negative correlation of the ADRB3 gene expression with the outcome of NB patients, and corroborate and strengthen the role of the β3-AR as molecular player capable of dampening anti-tumor immune responses by affecting multiple immune checkpoint signaling pathways. The gene discussed is ADRB3; the disease is neuroblastoma.